Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Interleukin-1 receptor antagonists, compositions, and methods of treatment

a technology of interleukin-1 and receptor, applied in the field of il1 receptor antagonists, can solve the problems of toxicity and secondary effects, limited treatment options for il-1-associated pathologies, and harmful actions of il-1

Inactive Publication Date: 2010-02-18
VALORISATION RECH SOC & COMMANDITE
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These non-competitive antagonists effectively inhibit IL-1 mediated events, providing anti-inflammatory responses for the treatment of chronic and acute inflammatory diseases with improved safety and efficacy compared to existing therapies.

Problems solved by technology

Despite its normally beneficial effects on an organism response to infection and injury, circumstances have come to light in which the actions of IL-1 are harmful.
The treatments available for these pathologies are currently limited.
They often result in toxicity and secondary effects.
Antagonists of the prior art are either competitive (e.g. soluble receptors, antibodies, cytokine mimetics), most often costly to produce or difficult to apply in vivo (e.g., antisense).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interleukin-1 receptor antagonists, compositions, and methods of treatment
  • Interleukin-1 receptor antagonists, compositions, and methods of treatment
  • Interleukin-1 receptor antagonists, compositions, and methods of treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of API-101 Peptide

[0194]One example of the efficacy of the compounds and methods of the present invention is represented by the results obtained with the identified peptide API-101 (SEQ ID NO 1: APRYTVELA).

[0195]All peptides described in the following examples have been synthesized according to the FMOC protocol of solid phase synthesis in an organic phase with protective groups. They have been purified with a yield of 70% with HPLC on a C18 column and eluted with an acetonitrile gradient of 10-60%. Their molecular weight have been verified by mass spectrometry. Of course as alluded above, when natural amino acids are used, they can be obtained by genetic engineering techniques as known in the art.

[0196]The proliferation effect of IL-1 was measured in A549 carcinoma cells in the presence of peptide API-101 (SEQ ID NO: 1) and of IL-1 (10 ng / ml) using the incorporation of tritiated thymidine method. A549 cells were pre-incubated (45 min.) with different concentrations of peptid...

example 2

Effect of Derivatives of API-101 Obtained by Alanine Scan

[0203]Having demonstrated a significant effect of the API-101 (SEQ ID NO: 1) antagonist, experiments were carried out to provide structure function relationship data for API-101 and derivatives, to identify the most important regions for activity. Alanine scan mutations were therefore performed on API-101 (SEQ ID NO: 1) (see FIG. 17 for the sequence of the peptides). Of course, other amino acids could have been used in the place of alanine to perform the scanning experiment.

In Vitro Characterization

[0204]A table summary of the results depending on the mutations performed is shown in FIG. 17.

[0205]Efficiencies and inhibitory activities of the mutated peptides were determined by measuring the inhibition of IL-1-induced PGE2 synthesis (see experimental protocol above in Example 1). API-101.1 (SEQ ID NO: 2) only had a slightly improved efficacy in endothelial cells and in chondrocytes as compared to the parent peptide API-101 (SEQ...

example 3

Effect of Further Optimization of API-101 on the Improvement of its Activity

[0208]To further improve the activity and to validate the alanine scan conclusions obtained on the region in API-101 important for its activity, the amino acids from the N-terminal end of the peptide were gradually truncated. FIG. 7 shows the sequence of the new peptides as well as the general pattern of optimization employed for API-101.

In Vitro Characterization:

[0209]IL-1β induces proliferation of human fibroblasts cells. Truncated peptides were assayed for IL-1β induced WI-38 (human lung fibroblasts) proliferation with the tritiated thymidine uptake protocol (see protocol example 1).

[0210]Relative to API-101 (SEQ ID NO: 1) which abolished 65% of IL-1R induced proliferation; API-101.10 (SEQ ID NO: 10) and API-101.11 (SEQ ID NO: 11) abolished 100% of IL-1B-induced proliferation (FIG. 8).

[0211]Determination of IL-1-induced PGE2 synthesis was also performed on API-101 truncated derivatives. FIG. 18 shows a su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
protease resistanceaaaaaaaaaa
serum stabilityaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R / IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.

Description

FIELD OF THE INVENTION[0001]The present invention relates to IL-1 receptor antagonists and methods of modulating IL-1 receptors activity with same. More specifically, the present invention is concerned with extracellular, non-competitive IL-1 receptor (IL1R / IL1RAcP) peptides and peptidomimetic antagonists, their identification and their therapeutic uses. More particularly, the present invention relates to peptide and peptidomimetic antagonists for use in the treatment of IL-1 associated diseases such as rheumatoid arthritis and inflammatory bowel disease. The present invention has application in the field of biochemistry and medicinal chemistry.BACKGROUND OF THE INVENTION[0002]Cytokines are generic terms for designating biologically active hormone-like proteins (interleukins, interferons, tumor necrosis factor, growth factors) that mediate their effects through a superfamily of receptors. Cytokines and their receptors constitute a powerful control network by which cells signal and c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/16C12N5/071A61K38/10A61K38/08C07K14/00C07K7/08C07K7/06
CPCC07K7/06A61K38/00A61P29/00
Inventor CHEMTOB, SYLVAINQUINIOU, CHRISTIANELUBELL, WILLIAM D.BEAUCHAMP, MARTINHANSFORD, KARL A.
Owner VALORISATION RECH SOC & COMMANDITE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com